Neu­ro­crine steers its ‘break­through’ tar­dive dysk­i­ne­sia drug to an FDA de­ci­sion

San Diego-based Neu­ro­crine Bio­sciences an­nounced that it has filed their NDA on a new drug for tar­dive dysk­i­ne­sia to­day, but the com­pa­ny isn’t wait­ing for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.